Generic Name and Formulations:
Benzphetamine HCl 50mg; scored tabs.
Various generic manufacturers
Indications for Benzphetamine:
Short-term adjunct in management of exogenous obesity.
Initially 25–50mg daily in mid-morning or mid-afternoon. Increase if needed to 25–50mg 1–3 times daily.
Advanced arteriosclerosis. Cardiovascular disease. Hypertension. Hyperthyroidism. Agitation. Drug or alcohol abuse. During or within 14 days of MAOIs. Pregnancy (Cat.X).
Discontinue after a few weeks as tolerance to anorectic effect occurs. Diabetes. Prescribe limited supply to prevent overdose. Nursing mothers: not recommended.
Hypertensive crisis with MAOIs. Blocks guanethidine. Altered insulin requirements. Potentiated by urinary alkalinizers. Antagonized by urinary acidifiers.
Abuse potential, impairment in hazardous activities, arrhythmias, hypertension, CNS overstimulation, psychosis, dry mouth, GI disturbances, urticaria, impotence.
Formerly known under the brand name Didrex.
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Once-Daily Oral Contraceptive for Men Shows Promise
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure